PharmaEssentia

PharmaEssentia is a fully integrated global biopharmaceutical company delivering therapeutic products for human diseases, with a focus on myeloproliferative neoplasms (MPNs) and other hematological diseases and cancers. Founded in 2003 by a group of Taiwanese-American executives and scientists, the company has commercial operations across North America, Europe, Japan, Korea, Hong Kong, Beijing, and Singapore. Its lead product BESREMi (ropeginterferon alfa-2b) is approved for polycythemia vera in multiple countries.

PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. The company's cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and designed to be compliant with U.S. FDA and EMA requirements. In 2024, the company was publicly listed on the Taiwan stock exchange. Ropeginterferon alfa-2b has been approved for polycythemia vera in several countries including Japan, Singapore, Malaysia, China, and Brazil.

• BESREMi (ropeginterferon alfa-2b)

  The first approved PV treatment that addresses the root cause of disease, designed to target the bone marrow and help manage blood cell counts in adults with polycythemia vera.

1. PharmaEssentia | Biopharmaceutical Blood Disorder Therapies
2. History | PharmaEssentia
3. Our Company | PharmaEssentia
4. About | PharmaEssentia
5. PharmaEssentia Corporation (Taiwan)